1y return+127.8%S&P 500 +20.9%
3y return+207.5%S&P 500 +68.5%
5y return+68.5%S&P 500 +74.5%
10y return+501.4%S&P 500 +256.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since June 30, 2016: $601 against $357 in the S&P 500.2
Opaleye Management Inc.S&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| LQDALiquidia Corporation | $195.1M | 17.7% | −3.8% |
| ETONEton Pharmaceuticals Inc | $103.5M | 9.4% | |
| HROWHarrow Inc | $101.9M | 9.2% | −15.3% |
| IRONDisc Medicine Inc | $62.5M | 5.7% | +103.1% |
| Urogen Pharma LtdCUSIP M96088105 | $53.0M | 4.8% | |
| Apogee Therapeutics IncCUSIP 03770N101 | $51.8M | 4.7% | |
| Meiragtx Hldgs PLCCUSIP G59665102 | $48.0M | 4.3% | +67.2% |
| Sol-gel Technologies LtdCUSIP M8694L137 | $37.1M | 3.4% | |
| RZLTRezolute Inc | $32.8M | 3.0% | |
| TGTXTg Therapeutics Inc | $29.4M | 2.7% | |
| IMMXImmix Biopharma Inc | $24.2M | 2.2% | New |
| Crescent Biopharma Inc.CUSIP G2545C104 | $23.7M | 2.2% | |
| STOKStoke Therapeutics Inc | $22.9M | 2.1% | |
| ACOGAlpha Cognition Inc | $20.9M | 1.9% | +13.0% |
| EWTXEdgewise Therapeutics Inc | $20.3M | 1.8% | |
| RVMDRevolution Medicines Inc | $18.7M | 1.7% | |
| GLUEMonte Rosa Therapeutics Inc | $18.0M | 1.6% | New |
| ALMSAlumis Inc | $15.5M | 1.4% | |
| CDXSCodexis Inc | $15.3M | 1.4% | |
| REPLReplimune Group Inc | $15.3M | 1.4% | New |
| Xoma Royalty CorporationCUSIP 98419J206 | $14.4M | 1.3% | +12.8% |
| MBXMbx Biosciences Inc | $14.4M | 1.3% | |
| RYTMRhythm Pharmaceuticals Inc | $13.6M | 1.2% | |
| EDITEditas Medicine Inc | $12.5M | 1.1% | +100.4% |
| PTGXProtagonist Therapeutics Inc | $12.3M | 1.1% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| LQDALiquidia Corporation | December 31, 2021 | +1537.1% | $195.1M |
| TRVITrevi Therapeutics Inc | December 31, 2022 | +866.3% | $5.8M |
| ALMSAlumis Inc | June 30, 2025 | +838.0% | $15.5M |
| HROWHarrow Inc | June 30, 2020 | +715.2% | $101.9M |
| MBXMbx Biosciences Inc | March 31, 2025 | +648.0% | $14.4M |
| ETONEton Pharmaceuticals Inc | June 30, 2020 | +564.3% | $103.5M |
| TGTXTg Therapeutics Inc | September 30, 2023 | +557.2% | $29.4M |
| PTGXProtagonist Therapeutics Inc | December 31, 2023 | +434.6% | $12.3M |
| RVMDRevolution Medicines Inc | June 30, 2025 | +409.1% | $18.7M |
| EWTXEdgewise Therapeutics Inc | March 31, 2022 | +318.9% | $20.3M |
Sold off last quarter
- CATXPerspective Therapeutics Inc was $19.5M
- Assertio Holdings IncCUSIP 04546C304 was $5.1M
- STROSutro Biopharma Inc was $4.7M
- TECXTectonic Therapeutic Inc was $3.8M
- RIGLRigel Pharmaceuticals Inc was $1.9M
- NXTCNextcure Inc was $1.5M
- Perspective Therapeutics IncCUSIP 46489V902 was $834K
- PLXProtalix Biotherapeutics Inc was $738K
- LBRXLb Pharmaceuticals Inc was $358K
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +40.7% | +14.8% |
| March 31, 2026 | +2.3% | −4.6% |
| December 31, 2025 | +12.2% | +2.4% |
| September 30, 2025 | +41.0% | +7.8% |
| June 30, 2025 | +6.7% | +10.5% |
| March 31, 2025 | −14.3% | −4.6% |
| December 31, 2024 | −1.0% | +2.1% |
| September 30, 2024 | +35.1% | +5.4% |
| June 30, 2024 | −9.5% | +4.0% |
| March 31, 2024 | +25.3% | +10.0% |
| December 31, 2023 | +20.0% | +11.2% |
| September 30, 2023 | −18.8% | −3.6% |
| June 30, 2023 | −0.7% | +8.3% |
| March 31, 2023 | +8.1% | +7.0% |
| December 31, 2022 | +8.7% | +7.1% |
| September 30, 2022 | +11.5% | −5.3% |
| June 30, 2022 | −28.6% | −16.5% |
| March 31, 2022 | −24.7% | −4.9% |
| December 31, 2021 | −10.7% | +10.7% |
| September 30, 2021 | −12.1% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Opaleye Management Inc. Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1595855&type=13F-HR&dateb=&owner=include&count=40CIK 1595855
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1595855/000142050626001803/Filed August 14, 2026 · accession 0001420506-26-001803